BD chooses China again for new Dx plant:
This article was originally published in Clinica
The Chinese work ethic, quality and drive are the reasons given by Linda Lin, country general manager (China) of US major Becton Dickinson for plans to set up its second Chinese manufacturing plant: BD Diagnostics - Rapid Diagnostics. The facility is due to open during the second quarter of 2008 and will, like BD's other plant, be located at Suzhou Industrial Park, Suzhou (Jiangsu province, east China). Initially, the plant will manufacture tests for diseases such as influenza and respiratory syncytial virus. But offerings will be expanded to include bacterial, parasitic and more viral diseases. The tests will be exported worldwide, including to Asia, Europe, Latin America and North America.
You may also be interested in...
GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.
Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.
A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.